Alivus Life Sciences Ltd share price logo

Glenmark Life Sciences Share Price

(ALIVUS)

Check the latest share price of Glenmark Life Sciences, details on performance, fundamentals, analyst ratings, peer comparison, financials, company news, analysis, and shareholding pattern for informed investing decisions.

₹1115.60.86%

as on 04:01PM, 09 May 2025

NSE

bell
The current prices are delayed by 15 mins, login to check live prices.

Glenmark Life Sciences Performance

Get real-time share price information, day’s high and low, historical returns and market stats.

  • Day's Low

    Day's High

    ₹1,069.1
    Day's Price Range
    ₹1,124.8
  • 52 Week's Low

    52 Week's High

    ₹755.95
    52-Week Price Range
    ₹1,335.1
1 Month Return+ 15.57 %
3 Month Return-7.33 %
1 Year Return+ 34.77 %
3 Year Return+ 154.67 %
5 Year Return+ 49.04 %
Previous Close₹1,106.10
Open₹1,075.30
Volume60.38K
Upper Circuit₹1,327.30
Lower Circuit₹884.90

Glenmark Life Sciences Fundamentals & Key Indicators

Check the fundamental ratios and key indicators of the company like P/E, P/B, PEG, Dividend yield etc.

Market Cap

₹13,680.51 Cr

Return on Equity (ROE)

21.07

PE Ratio (TTM)

0

Return on capital employed (ROCE)

27.94

Beta (LTM)

0.62

P/B Ratio

4.07

Dividend Yield

0

PEG Ratio

0

Quarterly Earnings Growth YOY

15.32

EPS (TTM)

0

Sector

Pharmaceuticals

Book Value

0

Technical Analysis

How to invest in Glenmark Life Sciences

Investing in Glenmark Life Sciences is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Glenmark Life Sciences or ALIVUS on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

For example: You can buy 10 shares of Glenmark Life Sciences or start an SIP based on the market price on each investment date.

You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Glenmark Life Sciences with just a few clicks!

Glenmark Life Sciences Stock's Interest Amongst Investors

5%

Period May 11, 2025 to Apr 11, 2025. Change in 30 Days vs previous period

Search interest for Alivus Life Sciences Ltd Stock has increased by 5% in the last 30 days, reflecting an upward trend in search activity.

Analysts Recommendation on Glenmark Life Sciences

Get updated buy, sell, and hold recommendations by analysts on Glenmark Life Sciences.

based on 4 analysts

BUY

80.00%

Buy

20.00%

Hold

0.00%

Sell

80% of analysts recommend a 'BUY' rating for Glenmark Life Sciences. Average target price of ₹1296.25

Source: S&P Global Market Intelligence

Analysts Forecast on Glenmark Life Sciences

Get share price movements and forecasts by analysts on Glenmark Life Sciences.

Glenmark Life Sciences price forecast by 4 analysts

Upside of16.19%

High

₹1360

Target

₹1296.25

Low

₹1150

Glenmark Life Sciences target price ₹1296.25, a slight upside of 16.19% compared to current price of ₹1115.6. According to 4 analysts rating.

Source: S&P Global Market Intelligence

Glenmark Life Sciences Financials

Get the annual and quarterly financial summary of Glenmark Life Sciences, including revenue, profit, loss and more.

Value in ₹ crore
DetailsQ'4 23Q'1 24Q'2 24Q'3 24Q'4 24
Revenue

(in ₹ Cr)

573 (0%)537 (6%)589 (10%)507 (14%)642 (27%)
Net Income

(in ₹ Cr)

119 (0%)98 (18%)111 (14%)95 (14%)137 (44%)
Net Profit Margin20.73% (0%)18.25% (12%)18.94% (4%)18.81% (1%)21.34% (13%)
Value in ₹ crore
Details2021202220232024
Total Assets

(in ₹ Cr)

1999 (0%)2472 (24%)2704 (9%)2855 (6%)
Total Liabilities

(in ₹ Cr)

1246 (0%)418 (66%)566 (35%)523 (8%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow

(in ₹ Cr)

195 (0%)388 (99%)598 (54%)306 (49%)414 (35%)

Glenmark Life Sciences Index Inclusions

Nifty Smallcap 250

₹15,080.45

-0.66 (-100%)

BSE Small-Cap

₹46,741.95

-0.3 (-140.78%)

BSE Healthcare

₹41,222.60

-0.16 (-65.34%)

Nifty MidSmallcap 400

₹17,953.75

-0.21 (-38.45%)

Nifty 500

₹21,675.55

-0.77 (-167.5%)

Glenmark Life Sciences Earnings and Dividends

View detailed summary of the earnings and dividend history of Glenmark Life Sciences.

  • Alivus Life Sciences Ltd Earnings Results

    Alivus Life Sciences Ltd’s net profit jumped 15.32% since last year same period to ₹136.96Cr in the Q3 2024-2025. On a quarterly growth basis, Alivus Life Sciences Ltd has generated 43.68% jump in its net profits since last 3-months.

    Read More about Earnings Results
  • Alivus Life Sciences Ltd Dividends October,2023

    In the quarter ending September 2023, Alivus Life Sciences Ltd has declared dividend of ₹22.50 - translating a dividend yield of 3.90%.

    Read More about Dividends

Glenmark Life Sciences Shareholding Pattern

View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Glenmark Life Sciences.

InvestorsHoldings %Quarterly Trend3M change
Promoter Holdings
74.99%
0.00
Foreign Institutions
6.57%
0.00
Mutual Funds
3.59%
0.00
Retail Investors
13.25%
0.00
Others
1.59%
0.00

Glenmark Life Sciences vs Peers

Compare market cap, revenue, PE, and other key metrics of Glenmark Life Sciences with its industry peers.

Company
Analyst View
Market Cap(in ₹ Cr)
5 Year CAGRDebt to Asset Ratio
Net Profit(in ₹ Cr)
Yearly Revenue(in ₹ Cr)
BUY13,680.519.81%0.514702,283
NA58.57-3.99%0.57346
NA2,053.5628.26%0.5158630
NA119.90-15.78%0.5012
NA135.7139.27%0.5111167

Insights on Alivus Life Sciences Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ALIVUS has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, ALIVUS stock has moved up by 2.6%

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 3.23% to 3.59% in Mar 2025 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 58.8% return, outperforming this stock by 24.1%

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 13.40% to 13.25% in Mar 2025 quarter

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 6.74% to 6.57% in Mar 2025 quarter

  • imgNEGATIVE IMPACT

    Promoter Holding Down

    img

    Promoters have decreased holdings from 75.00% to 74.99% in Mar 2025 quarter

About Glenmark Life Sciences

Glenmark Life Sciences Private Limited (formerly Zorg Laboratories Private Limited) was incorporated as a private limited company on 23 June 2011. It was acquired by Glenmark Pharmaceuticals Limited in July 2018, and was converted to a public company in August 2018. Operating as a wholly-owned subsidiary of Glenmark Pharmaceuticals, the company is engaged in the development, manufacture, and marketing of active pharmaceutical ingredients (APIs). The company has Research and Development (R&D) facilities in Mahape, Ankleshwar, and Dahej, while its manufacturing facilities are located in Ankleshwar, Dahej, Mohol, and Kurkumbh. On 13 August 2018, Glenmark Life Sciences allotted 4,500,090 equity shares of Rs. 10 each upon conversion of a loan given to the Director, and 15,000,000 shares to its parent company Glenmark Pharmaceuticals under preferential allotment. The company recently concluded its IPO, of a total of 21,022,222 equity shares, raising Rs. 15136 million. All of the outstanding purchase consideration was repaid from the proceeds of the IPO, and the company’s equity shares are now listed on both the BSE and NSE.

Revenue: ₹641.84Cr as on December 2024 (Q4 24)
Net Profit: ₹136.96Cr as on December 2024 (Q4 24)
Listing date: 06 Aug, 2021
Chairperson Name: Glenn Saldanha
OrganisationAlivus Life Sciences Ltd
IndustryPharmaceuticals
CEOGlenn Saldanha
E-voting on sharesClick here to vote

Indian Mutual Funds that own Glenmark Life Sciences

Check out the Mutual Funds with significant holdings in Glenmark Life Sciences.

FAQs

What is Alivus Life Sciences Ltd price today?

Alivus Life Sciences Ltd share price today stands at ₹1115.6, Open: ₹1075.3, Previous Close: ₹1106.1, High: ₹1124.8, Low: ₹1069.1, 52 Week High: ₹1335.1, 52 Week Low: ₹755.95.

How to Buy Alivus Life Sciences Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Alivus Life Sciences Ltd shares

What are today's traded volumes of Alivus Life Sciences Ltd?

Today's traded volume of Alivus Life Sciences Ltd(ALIVUS) is 60.38K.

What is today's market capitalisation of Alivus Life Sciences Ltd?

Today's market capitalisation of Alivus Life Sciences Ltd(ALIVUS) is ₹13,680.51 Cr.

What is the 52 Week High and Low Range of Alivus Life Sciences Ltd?

Alivus Life Sciences Ltd (ALIVUS)
Price
52 Week High
₹1335.1
52 Week Low
₹755.95

How much percentage Alivus Life Sciences Ltd is down from its 52 Week High?

Alivus Life Sciences Ltd (ALIVUS) share price is ₹1115.6. It is down -16.44% from its 52 Week High price of ₹1335.1

How much percentage Alivus Life Sciences Ltd is up from its 52 Week low?

Alivus Life Sciences Ltd (ALIVUS) share price is ₹1115.6. It is up 47.58% from its 52 Week Low price of ₹755.95